BEVESPI AEROSPHERE Rx
Generic Name and Formulations:
Glycopyrrolate 9mcg, formoterol fumarate 4.8mcg; per inhalation; metered-dose inhaler.
Indications for BEVESPI AEROSPHERE:
Long-term maintenance treatment of airflow obstruction in COPD, including chronic bronchitis and/or emphysema.
Limitations Of use:
Not for the relief of acute bronchospasm or for the treatment of asthma.
2 inhalations twice daily (in the AM + PM). Max 2 inhalations twice daily.
LABA use in asthma patients without use of long-term control medication.
LABAs increase risk of asthma-related death. Not recommended for treating asthma. Do not initiate in patients during acutely deteriorating or potentially life-threatening COPD episodes. Not for treating acute symptoms. Prescribe a short-acting β2-agonist for acute symptoms; monitor for increased need. Do not exceed recommended dose. Discontinue immediately and treat if paradoxical bronchospasm or immediate hypersensitivity reactions occur; use alternative therapy. Cardiovascular disorders (eg, coronary insufficiency, cardiac arrhythmias, hypertension). Convulsive disorders. Thyrotoxicosis. Hyperresponsiveness to sympathomimetics. Diabetes. Ketoacidosis. Hypokalemia. Hyperglycemia. Narrow-angle glaucoma. Urinary retention. Prostatic hyperplasia. Bladder-neck obstruction. Hepatic disease; monitor. Severe renal impairment or ESRD requiring dialysis. Pregnancy (Cat.C). Labor & delivery. Nursing mothers: not recommended.
Anticholinergic + long-acting beta-2 agonist (LABA).
Not for use with other drugs containing LABAs. Caution with concomitant other adrenergic drugs; may potentiate sympathetic effects. Concomitant xanthine derivatives, steroids, or diuretics may potentiate hypokalemia. Caution with non-K+-sparing diuretics. Extreme caution with MAOIs, tricyclics, or others that prolong QTc interval. Antagonized by β-blockers; if needed, use cardioselective agents if no acceptable alternatives. Additive effects with concomitant other anticholinergic-containing drugs; avoid.
UTI, cough; paradoxical bronchospasm, hypersensitivity reactions, cardiovascular effects.
Inhalation aerosol—10.7g (120 inh)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- First-Line Osimertinib Effective Regardless of PD-L1 Expression in EGFR-Mutated NSCLC
- irAEs Associated With Prolonged PFS and OS in NSCLC
- Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype
- The Identification of a Potential Early Plasma Biomarker for Kidney Cancer
- Pembrolizumab Plus Chemotherapy Extended Survival Longer Than Chemotherapy Alone: Study